VCs Applaud JOBS Act, But Will It Open Doors For Life Science Start-Ups?
This article was originally published in The Pink Sheet Daily
Executive Summary
“Emerging growth” start-ups will enjoy less regulation during their first five years as public companies, easing the burden on new listings while giving IPO prospects more leverage against buyers.
You may also be interested in...
Insiders Back Cebix With $30.9M, As New CEO Prepares For Phase II Trial
The La Jolla, Calif.-based start-up will soon begin a mid-stage trial on Ersatta, a long-acting drug to treat diabetic complications.
Forma To Play To Its Strengths WIth Genentech Deal
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
Gilead Takes Calistoga To Boost Cancer Effort
Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.